Market Analysis and Insights: Global Cell and Gene Therapy Manufacturing QC Market
The global Cell and Gene Therapy Manufacturing QC market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Cell and Gene Therapy Manufacturing QC is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Cell and Gene Therapy Manufacturing QC is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Cell and Gene Therapy Manufacturing QC is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Cell and Gene Therapy Manufacturing QC include Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG and Merck KGaA, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Cell and Gene Therapy Manufacturing QC market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Cell and Gene Therapy Manufacturing QC, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cell and Gene Therapy Manufacturing QC, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cell and Gene Therapy Manufacturing QC revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Cell and Gene Therapy Manufacturing QC market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Cell and Gene Therapy Manufacturing QC revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bio-Techne Corporation, BioMerieux SA, Catalent, Inc., Charles River Laboratories International Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Intertek Group plc, Lonza Group AG and Merck KGaA, etc.
By Company
Bio-Techne Corporation
BioMerieux SA
Catalent, Inc.
Charles River Laboratories International Inc.
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Intertek Group plc
Lonza Group AG
Merck KGaA
Sartorius AG
SGS S.A.
Sistemic Scotland Limited
Thermo Fisher Scientific Inc.
Vigene Biosciences, Inc.
WuXi AppTec
Segment by Type
Safety Testing
Purity Testing
Potency Testing
Identity Testing
Stability Testing
Segment by Application
Precision Therapy
Biological Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cell and Gene Therapy Manufacturing QC in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cell and Gene Therapy Manufacturing QC companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell and Gene Therapy Manufacturing QC revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell and Gene Therapy Manufacturing QC Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Safety Testing
1.2.3 Purity Testing
1.2.4 Potency Testing
1.2.5 Identity Testing
1.2.6 Stability Testing
1.3 Market by Application
1.3.1 Global Cell and Gene Therapy Manufacturing QC Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Precision Therapy
1.3.3 Biological Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell and Gene Therapy Manufacturing QC Market Perspective (2018-2029)
2.2 Global Cell and Gene Therapy Manufacturing QC Growth Trends by Region
2.2.1 Cell and Gene Therapy Manufacturing QC Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cell and Gene Therapy Manufacturing QC Historic Market Size by Region (2018-2023)
2.2.3 Cell and Gene Therapy Manufacturing QC Forecasted Market Size by Region (2024-2029)
2.3 Cell and Gene Therapy Manufacturing QC Market Dynamics
2.3.1 Cell and Gene Therapy Manufacturing QC Industry Trends
2.3.2 Cell and Gene Therapy Manufacturing QC Market Drivers
2.3.3 Cell and Gene Therapy Manufacturing QC Market Challenges
2.3.4 Cell and Gene Therapy Manufacturing QC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Cell and Gene Therapy Manufacturing QC by Players
3.1.1 Global Cell and Gene Therapy Manufacturing QC Revenue by Players (2018-2023)
3.1.2 Global Cell and Gene Therapy Manufacturing QC Revenue Market Share by Players (2018-2023)
3.2 Global Cell and Gene Therapy Manufacturing QC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Cell and Gene Therapy Manufacturing QC, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Cell and Gene Therapy Manufacturing QC Market Concentration Ratio
3.4.1 Global Cell and Gene Therapy Manufacturing QC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell and Gene Therapy Manufacturing QC Revenue in 2022
3.5 Global Key Players of Cell and Gene Therapy Manufacturing QC Head office and Area Served
3.6 Global Key Players of Cell and Gene Therapy Manufacturing QC, Product and Application
3.7 Global Key Players of Cell and Gene Therapy Manufacturing QC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell and Gene Therapy Manufacturing QC Breakdown Data by Type
4.1 Global Cell and Gene Therapy Manufacturing QC Historic Market Size by Type (2018-2023)
4.2 Global Cell and Gene Therapy Manufacturing QC Forecasted Market Size by Type (2024-2029)
5 Cell and Gene Therapy Manufacturing QC Breakdown Data by Application
5.1 Global Cell and Gene Therapy Manufacturing QC Historic Market Size by Application (2018-2023)
5.2 Global Cell and Gene Therapy Manufacturing QC Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
6.2 North America Cell and Gene Therapy Manufacturing QC Market Size by Type
6.2.1 North America Cell and Gene Therapy Manufacturing QC Market Size by Type (2018-2023)
6.2.2 North America Cell and Gene Therapy Manufacturing QC Market Size by Type (2024-2029)
6.2.3 North America Cell and Gene Therapy Manufacturing QC Market Share by Type (2018-2029)
6.3 North America Cell and Gene Therapy Manufacturing QC Market Size by Application
6.3.1 North America Cell and Gene Therapy Manufacturing QC Market Size by Application (2018-2023)
6.3.2 North America Cell and Gene Therapy Manufacturing QC Market Size by Application (2024-2029)
6.3.3 North America Cell and Gene Therapy Manufacturing QC Market Share by Application (2018-2029)
6.4 North America Cell and Gene Therapy Manufacturing QC Market Size by Country
6.4.1 North America Cell and Gene Therapy Manufacturing QC Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2023)
6.4.3 North America Cell and Gene Therapy Manufacturing QC Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
7.2 Europe Cell and Gene Therapy Manufacturing QC Market Size by Type
7.2.1 Europe Cell and Gene Therapy Manufacturing QC Market Size by Type (2018-2023)
7.2.2 Europe Cell and Gene Therapy Manufacturing QC Market Size by Type (2024-2029)
7.2.3 Europe Cell and Gene Therapy Manufacturing QC Market Share by Type (2018-2029)
7.3 Europe Cell and Gene Therapy Manufacturing QC Market Size by Application
7.3.1 Europe Cell and Gene Therapy Manufacturing QC Market Size by Application (2018-2023)
7.3.2 Europe Cell and Gene Therapy Manufacturing QC Market Size by Application (2024-2029)
7.3.3 Europe Cell and Gene Therapy Manufacturing QC Market Share by Application (2018-2029)
7.4 Europe Cell and Gene Therapy Manufacturing QC Market Size by Country
7.4.1 Europe Cell and Gene Therapy Manufacturing QC Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2023)
7.4.3 Europe Cell and Gene Therapy Manufacturing QC Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
8.2 China Cell and Gene Therapy Manufacturing QC Market Size by Type
8.2.1 China Cell and Gene Therapy Manufacturing QC Market Size by Type (2018-2023)
8.2.2 China Cell and Gene Therapy Manufacturing QC Market Size by Type (2024-2029)
8.2.3 China Cell and Gene Therapy Manufacturing QC Market Share by Type (2018-2029)
8.3 China Cell and Gene Therapy Manufacturing QC Market Size by Application
8.3.1 China Cell and Gene Therapy Manufacturing QC Market Size by Application (2018-2023)
8.3.2 China Cell and Gene Therapy Manufacturing QC Market Size by Application (2024-2029)
8.3.3 China Cell and Gene Therapy Manufacturing QC Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
9.2 Asia Cell and Gene Therapy Manufacturing QC Market Size by Type
9.2.1 Asia Cell and Gene Therapy Manufacturing QC Market Size by Type (2018-2023)
9.2.2 Asia Cell and Gene Therapy Manufacturing QC Market Size by Type (2024-2029)
9.2.3 Asia Cell and Gene Therapy Manufacturing QC Market Share by Type (2018-2029)
9.3 Asia Cell and Gene Therapy Manufacturing QC Market Size by Application
9.3.1 Asia Cell and Gene Therapy Manufacturing QC Market Size by Application (2018-2023)
9.3.2 Asia Cell and Gene Therapy Manufacturing QC Market Size by Application (2024-2029)
9.3.3 Asia Cell and Gene Therapy Manufacturing QC Market Share by Application (2018-2029)
9.4 Asia Cell and Gene Therapy Manufacturing QC Market Size by Region
9.4.1 Asia Cell and Gene Therapy Manufacturing QC Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Cell and Gene Therapy Manufacturing QC Market Size by Region (2018-2023)
9.4.3 Asia Cell and Gene Therapy Manufacturing QC Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Type
10.2.1 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Application
10.3.1 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Country
10.4.1 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Cell and Gene Therapy Manufacturing QC Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bio-Techne Corporation
11.1.1 Bio-Techne Corporation Company Details
11.1.2 Bio-Techne Corporation Business Overview
11.1.3 Bio-Techne Corporation Cell and Gene Therapy Manufacturing QC Introduction
11.1.4 Bio-Techne Corporation Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.1.5 Bio-Techne Corporation Recent Developments
11.2 BioMerieux SA
11.2.1 BioMerieux SA Company Details
11.2.2 BioMerieux SA Business Overview
11.2.3 BioMerieux SA Cell and Gene Therapy Manufacturing QC Introduction
11.2.4 BioMerieux SA Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.2.5 BioMerieux SA Recent Developments
11.3 Catalent, Inc.
11.3.1 Catalent, Inc. Company Details
11.3.2 Catalent, Inc. Business Overview
11.3.3 Catalent, Inc. Cell and Gene Therapy Manufacturing QC Introduction
11.3.4 Catalent, Inc. Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.3.5 Catalent, Inc. Recent Developments
11.4 Charles River Laboratories International Inc.
11.4.1 Charles River Laboratories International Inc. Company Details
11.4.2 Charles River Laboratories International Inc. Business Overview
11.4.3 Charles River Laboratories International Inc. Cell and Gene Therapy Manufacturing QC Introduction
11.4.4 Charles River Laboratories International Inc. Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.4.5 Charles River Laboratories International Inc. Recent Developments
11.5 Eurofins Scientific SE
11.5.1 Eurofins Scientific SE Company Details
11.5.2 Eurofins Scientific SE Business Overview
11.5.3 Eurofins Scientific SE Cell and Gene Therapy Manufacturing QC Introduction
11.5.4 Eurofins Scientific SE Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.5.5 Eurofins Scientific SE Recent Developments
11.6 F. Hoffmann-La Roche Ltd
11.6.1 F. Hoffmann-La Roche Ltd Company Details
11.6.2 F. Hoffmann-La Roche Ltd Business Overview
11.6.3 F. Hoffmann-La Roche Ltd Cell and Gene Therapy Manufacturing QC Introduction
11.6.4 F. Hoffmann-La Roche Ltd Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.6.5 F. Hoffmann-La Roche Ltd Recent Developments
11.7 Intertek Group plc
11.7.1 Intertek Group plc Company Details
11.7.2 Intertek Group plc Business Overview
11.7.3 Intertek Group plc Cell and Gene Therapy Manufacturing QC Introduction
11.7.4 Intertek Group plc Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.7.5 Intertek Group plc Recent Developments
11.8 Lonza Group AG
11.8.1 Lonza Group AG Company Details
11.8.2 Lonza Group AG Business Overview
11.8.3 Lonza Group AG Cell and Gene Therapy Manufacturing QC Introduction
11.8.4 Lonza Group AG Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.8.5 Lonza Group AG Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Cell and Gene Therapy Manufacturing QC Introduction
11.9.4 Merck KGaA Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.9.5 Merck KGaA Recent Developments
11.10 Sartorius AG
11.10.1 Sartorius AG Company Details
11.10.2 Sartorius AG Business Overview
11.10.3 Sartorius AG Cell and Gene Therapy Manufacturing QC Introduction
11.10.4 Sartorius AG Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.10.5 Sartorius AG Recent Developments
11.11 SGS S.A.
11.11.1 SGS S.A. Company Details
11.11.2 SGS S.A. Business Overview
11.11.3 SGS S.A. Cell and Gene Therapy Manufacturing QC Introduction
11.11.4 SGS S.A. Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.11.5 SGS S.A. Recent Developments
11.12 Sistemic Scotland Limited
11.12.1 Sistemic Scotland Limited Company Details
11.12.2 Sistemic Scotland Limited Business Overview
11.12.3 Sistemic Scotland Limited Cell and Gene Therapy Manufacturing QC Introduction
11.12.4 Sistemic Scotland Limited Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.12.5 Sistemic Scotland Limited Recent Developments
11.13 Thermo Fisher Scientific Inc.
11.13.1 Thermo Fisher Scientific Inc. Company Details
11.13.2 Thermo Fisher Scientific Inc. Business Overview
11.13.3 Thermo Fisher Scientific Inc. Cell and Gene Therapy Manufacturing QC Introduction
11.13.4 Thermo Fisher Scientific Inc. Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.13.5 Thermo Fisher Scientific Inc. Recent Developments
11.14 Vigene Biosciences, Inc.
11.14.1 Vigene Biosciences, Inc. Company Details
11.14.2 Vigene Biosciences, Inc. Business Overview
11.14.3 Vigene Biosciences, Inc. Cell and Gene Therapy Manufacturing QC Introduction
11.14.4 Vigene Biosciences, Inc. Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.14.5 Vigene Biosciences, Inc. Recent Developments
11.15 WuXi AppTec
11.15.1 WuXi AppTec Company Details
11.15.2 WuXi AppTec Business Overview
11.15.3 WuXi AppTec Cell and Gene Therapy Manufacturing QC Introduction
11.15.4 WuXi AppTec Revenue in Cell and Gene Therapy Manufacturing QC Business (2018-2023)
11.15.5 WuXi AppTec Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Bio-Techne Corporation
BioMerieux SA
Catalent, Inc.
Charles River Laboratories International Inc.
Eurofins Scientific SE
F. Hoffmann-La Roche Ltd
Intertek Group plc
Lonza Group AG
Merck KGaA
Sartorius AG
SGS S.A.
Sistemic Scotland Limited
Thermo Fisher Scientific Inc.
Vigene Biosciences, Inc.
WuXi AppTec
*If Applicable.